In summary, using human HCC data and mouse models with three approaches to inhibit Gal-1, this study unequivocally demonstrates the significant role of miR-22-Gal-1 in tumor metabolism and immune modulation, offering a compelling therapeutic target for treating HCC. Here, LGALS1 is linked to hepatocellular carcinoma.